Generics Industry Fails To Match Last Year’s Growth In First Quarter

Firms Including Sandoz, Teva And Amneal Struggle With Prior-Year Comparison

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

pandemic
Companies failed to match the record-breaking numbers of Q1 2020, in the quarter ended 31 March 2021 • Source: Alamy

After experiencing an exceptionally strong performance due to COVID-induced stockpiling and panic buying in the first quarter of last year, the generics industry largely saw revenues drop due to pandemic-related challenges in first quarter of 2021.

The companies that saw unprecedented growth due to the first wave of COVID-19 (see sidebar) failed to match the record-breaking...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business